A research team from the Lausanne Branch of the Ludwig Institute for Cancer Research and the École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland has pioneered a groundbreaking method to regulate the activity of CAR-T cells as needed. The latest edition of Nature Chemical Biology features the design and preclinical evaluation results of this innovative type of CAR-T cells, verifying their effectiveness and controllability in mouse cancer models. This significant advancement establishes a technological framework for extending CAR-T therapy to more complex situations, such as the treatment of solid tumors, and offers hope that more patients will be able to reap the benefits of this precise immunotherapy in the future.
